A
$ Value
$0
Shares
20,000
Price
$0
Filed
Dec 22
Insider
Name
Margrave David R.
Title
Chief Financial Officer
CIK
0001813162
Roles
Officer
Transaction Details
Transaction Date
2025-12-18
Code
A
Table
Derivative
Ownership
Direct
Equity Swap
No
Shares After
20,000
Footnotes
The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 24-month period commencing January 18, 2026.